<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01360970</url>
  </required_header>
  <id_info>
    <org_study_id>EU 2009-016055-22</org_study_id>
    <nct_id>NCT01360970</nct_id>
  </id_info>
  <brief_title>Hepatitis A Vaccine in Patients With Immunomodulating Drugs</brief_title>
  <official_title>Hepatitis A Vaccination in Patients With Rheumatoid Arthritis Treated With TNF-inhibitors and/or Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lars Rombo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sormland County Council, Sweden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatitis A vaccine is the most frequently used traveller's vaccine, yet data on its ability&#xD;
      to induce protective immunity in immunosuppressed travellers are scarce. The investigators&#xD;
      assess the hepatitis A virus (HAV) antibody response in patients with rheumatoid arthritis&#xD;
      (RA) treated with Tumor Necrosis Factor (TNF) - inhibitors and/or methotrexate (Mtx).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods: Parameters registered at baseline were: age, sex, duration of disease, medications,&#xD;
      activity of disease (Visual Analogue Scale=VAS, Health Assessment Questionnaire Disability&#xD;
      Index = HAQ, Disease Activity Score =DAS-28, CRP and total IgG in plasma). Hepatitis A&#xD;
      vaccine (Epaxal or Havrix) were given at 0 and 6 months. Hepatitis A virus (HAV) antibodies&#xD;
      is measured before vaccination and at month 1, 6 (before dose 2), 7 and 12 with quantitative&#xD;
      HAV IgG, using the HAVAb-IgG Architect System, and by the HAVAB 2.0 assay on the AxSYM&#xD;
      machine from Abbott. The level of protective immunity to HAV is defined as HAV IgG &gt;&#xD;
      10mIU/mL.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>seroconversion after a single dose of hepatitis A vaccine</measure>
    <time_frame>one month after dose</time_frame>
    <description>ELISA-titers are determined before first dose and at 1 and 6 months later</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>seroconversion rates after a second dose of hepatitis A vaccine</measure>
    <time_frame>12 monrths</time_frame>
    <description>We determine seroconversion rates before the second vaccine dose ( 6 months after the first) and at 1 and 6 months after the second dose</description>
  </secondary_outcome>
  <enrollment type="Actual">68</enrollment>
  <condition>Response to Hepatitis A Vaccine</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>hepatitis A vaccine ( HAVRIX or EPAXAL)</intervention_name>
    <description>1.0 ml im ( Havrix) and 0.5 ml im (Epaxal. Both vaccines are given two times with 6 months interval</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of rheumatoid arthritis&#xD;
&#xD;
          -  TNF-alfa blocker and / or methotraxate in use as a medication against RA&#xD;
&#xD;
          -  A desire to get protected against hepatitis A&#xD;
&#xD;
          -  Men and women age 18-65 years&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Women of childbearing potential must use effective contraception -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with rituximab within 9 months before study start&#xD;
&#xD;
          -  Known previous hepatitis A infection&#xD;
&#xD;
          -  Previous vaccination against hepatitis A&#xD;
&#xD;
          -  Allergy to eggs or formaldehyde&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Excessive use of alcohol&#xD;
&#xD;
          -  Mental retardation&#xD;
&#xD;
          -  Acute disease at the time of examination (fever &gt; 38 degrees)&#xD;
&#xD;
          -  Volunteer works as an employee of the researchers&#xD;
&#xD;
          -  Previous vaccination against hepatitis A&#xD;
&#xD;
          -  Egg-, henprotein- or formaldehyde allergy&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Excessive use of alcohol&#xD;
&#xD;
          -  Another vaccine given within a month&#xD;
&#xD;
          -  Acute disease at the time of examination (fever &gt; 38 degrees)&#xD;
&#xD;
          -  Not suitable for other reason in the investigator's opinion (other serious disease,&#xD;
             i.e. AIDS/HIV-positive, cancer with ongoing cytostatic treatment)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>lars rombo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept infectious diseases</name>
      <address>
        <city>Helsingfors</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept infectious diseases</name>
      <address>
        <city>Eskilstuna</city>
        <zip>631 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept infectious diseases</name>
      <address>
        <city>Karlstad</city>
        <zip>651 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of infectious diseases</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>May 24, 2011</study_first_submitted>
  <study_first_submitted_qc>May 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2011</study_first_posted>
  <last_update_submitted>November 17, 2015</last_update_submitted>
  <last_update_submitted_qc>November 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sormland County Council, Sweden</investigator_affiliation>
    <investigator_full_name>Lars Rombo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>hepatitis A vaccine</keyword>
  <keyword>TNF-alfa inhibitory drugs</keyword>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>methotrexate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

